## COR: Cencora, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -5.7% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($322.62)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Amundi Has $500.89 Million Stock Holdings in Cencora, Inc. $COR**
- Source: MarketBeat | 20251206T160748 | Somewhat-Bullish | Relevance: 99%
-  Amundi significantly increased its stake in Cencora, Inc. (NYSE:COR) by 17.0%, now holding 1,720,278 shares valued at $500.89 million. Despite this institutional accumulation, company insiders have been net sellers, offloading shares worth approximately $14.1 million. Cencora itself reported strong financials, slightly exceeding quarterly EPS and revenue expectations and raising its quarterly dividend.

**2. Cencora, Inc. $COR Shares Sold by California Public Employees Retirement System**
- Source: MarketBeat | 20251208T094640 | Neutral | Relevance: 98%
- Cencora, Inc. (NYSE:COR) saw its shares sold by the California Public Employees Retirement System, which trimmed its stake by 11% during the second quarter. Corporate insiders have also been net sellers. Despite this, analysts are generally positive, with several firms raising price targets, resulting in a "Moderate Buy" consensus rating.

**3. Federated Hermes Inc. Increases Stock Holdings in Cencora, Inc. $COR**
- Source: MarketBeat | 20251207T121247 | Bullish | Relevance: 98%
- Federated Hermes Inc. significantly increased its stake in Cencora, Inc. (NYSE:COR) by 24.1% in the second quarter, acquiring an additional 133,907 shares to own a total of 688,656 shares valued at approximately $206.5 million. Cencora recently reported better-than-expected quarterly earnings of $3.84 EPS and revenue of $83.73 billion, while also raising its quarterly dividend to $0.60 per share. Despite some insider selling, institutional investors own a substantial 97.52% of the company, and analysts generally maintain a "Moderate Buy" rating with an average price target of $371.09.

**4. Marshall Wace LLP Has $96.66 Million Holdings in Cencora, Inc. $COR**
- Source: MarketBeat | 20251206T115440 | Somewhat-Bullish | Relevance: 98%
-  Marshall Wace LLP increased its stake in Cencora, Inc. (NYSE:COR) by 24.7% in Q2, bringing its total holdings to $96.66 million. Despite insider selling by Chairman Steven Collis and CEO Robert Mauch, analyst sentiment remains generally positive with a "Moderate Buy" consensus and an average price target of $371.09. The company also recently announced an increased quarterly dividend of $0.60 per share.

**5. Gabelli Funds LLC Reduces Holdings in Cencora, Inc. $COR**
- Source: MarketBeat | 20251209T094529 | Neutral | Relevance: 98%
-  Gabelli Funds LLC decreased its stake in Cencora, Inc. (NYSE:COR) by 6.6% in the second quarter, selling 3,355 shares and now owning 47,770 shares valued at approximately $14.32 million. Concurrently, other institutional investors adjusted their positions, and company insiders, including CEO Robert P. Mauch and Chairman Steven H. Collis, sold significant shares. Despite these reductions, analysts maintain a "Moderate Buy" consensus rating for Cencora with an average target price of $373.50, and the company recently increased its quarterly dividend.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-11 | JP Morgan | $417 | $344 | +21% |
| 2025-11-11 | Wells Fargo | $405 | $354 | +14% |
| 2025-11-10 | TD Cowen | $400 | $350 | +14% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-11 | JP Morgan | main | Overweight |
| 2025-11-11 | Wells Fargo | main | Overweight |
| 2025-11-10 | TD Cowen | main | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 47.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (+4.1%)
- Blackrock Inc.: 10.2% (+5.7%)
- JPMORGAN CHASE & CO: 4.8% (+139.5%)
- State Street Corpora: 4.7% (+9.3%)
- Price (T.Rowe) Assoc: 4.0% (-0.9%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 3 raises (avg +17%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.82 indicates undervaluation relative to growth. Quality metrics strong (ROE 124%). Balance sheet: $2.9B free cash flow. Analyst sentiment positive (3 raises, avg +17%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $65.5B |
| Beta | 0.63 |
| 52W Range | $223.92 - $377.54 |
| Short Interest | 4.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.82 |
| Forward P/E | 17.3 |
| Current P/E | 19.1 |
| YoY Growth | 10.6% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at -5.7% (minimal 5-day change). Below STRENGTH zone by 8.7pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.13x) but short-term weakness (below SMA20). MACD histogram bearish (-5.14), momentum weakening.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -5.66% (CS: 4) | Weak |
| RSI_14 | 39.0 | Neutral |
| MACD Histogram | -5.14 | Bearish |
| vs SMA20 | 0.941x | Below |
| vs SMA50 | 0.995x | Below |
| vs SMA200 | 1.130x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $337.82
- **Stop Loss:** $322.62 (4.5% risk)
- **Target:** $353.02 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 32
- **Position Value:** $10,810.24
- **Portfolio %:** 10.81%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-04 (Est: $4.07)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.79 | $3.84 | +1.4% |
| 2025Q2 | $3.84 | $4.00 | +4.2% |
| 2025Q1 | $4.10 | $4.42 | +7.9% |
| 2024Q4 | $3.52 | $3.73 | +6.0% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*